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Patients with cancer have been disproportionately affected by the COVID-19 pandemic. This effect has
included the adverse outcomes in patients with cancer who develop COVID-19, the impact of the COVID-
19 pandemic on the delivery of cancer care, and the severe disruption to cancer research. However, patients
with cancer are a heterogeneous population, and recent studies have nowdocumented factors that allow risk
stratification of patients with cancer in order to optimize care. In this review, we highlight data at the intersec-
tion of COVID-19 and cancer, including the biological interplay between the two diseases and practical rec-
ommendations for the treatment of patients with cancer during the pandemic. We additionally discuss the
potential long-lasting impact of the pandemic on cancer care due to its deleterious effect on cancer research,
as well as biological insights from the cancer research community that could help develop novel therapies for
all patients with COVID-19.INTRODUCTION
The severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) virus has resulted in an ongoing pandemic;
at the time of writing (September 2020) over 30 million peo-
ple have developed the resulting illness, COVID-19, causing
more than 970,000 deaths worldwide (New York Times,
2020). Although the pandemic has, either directly or indi-
rectly, had an impact on the entire world, certain subgroups
of patients have been disproportionately affected. In partic-
ular, the Centers for Disease Control and Prevention (CDC)
in the United States identify patients with certain medical
conditions as being at particularly high risk of developing
severe COVID-19 illness; among these are patients with
cancer (CDC, 2020).
Patients with cancer have been found to have particularly
adverse outcomes with COVID-19 (Garassino et al., 2020; Gian-
nakoulis et al., 2020; Kuderer et al., 2020; Pinato et al., 2020; Riv-
era et al., 2020; Saini et al., 2020; Westblade et al., 2020). More-
over, care delivery for chronic conditions, including cancer, has
been at least partially disrupted during the peaks of the
pandemic due to prioritization and limitations on resources.
Health care providers and patients have also had to continually
reassess the balance between the risks and the benefits of can-
cer-directed interventions within the context of the added risk of
infection by SARS-CoV-2 (Schrag et al., 2020). In addition to this
disruption in cancer care delivery, cancer research has also beenupended during the pandemic, including basic, translational,
and clinical cancer research.
This review aims to comprehensively detail the relationship
between COVID-19 and cancer, from biological interactions
to specific clinical characteristics of patients with cancer who
develop COVID-19, in the context of the reduced cancer care
that the pandemic has brought on. The review additionally
highlights the potential lasting effect of COVID-19 on cancer
care attributable to the significant interruption of cancer
research.
Interplay of SARS-CoV-2 and Cancer Biology: Risks and
Opportunities
Multiple pieces of evidence have indicated an interplay between
the biology of SARS-CoV-2 and cancer (Box 1). Evidence sug-
gests that patients with cancer are more likely to be infected
by SARS-CoV-2 (Liang et al., 2020; Rogado et al., 2020), more
likely develop a severe COVID-19 infection (Garassino et al.,
2020; Kuderer et al., 2020; Westblade et al., 2020), and more
likely to die as a result of COVID-19 (Garassino et al., 2020; Ku-
derer et al., 2020; Saini et al., 2020; Westblade et al., 2020; Wil-
liamson et al., 2020). In contrast, certain anti-neoplastic hormon-
al treatments have been suggested to potentially play a
protective role in patientswith SARS-CoV-2 infections (Stopsack
et al., 2020). This clinical interaction between COVID-19 and
cancer therefore warrants discussion of the potential underlying
biological mechanisms.Cancer Cell 38, November 9, 2020 ª 2020 Elsevier Inc. 629
Box 1. Interplay of SARS-CoV-2 and Cancer Biology
d SARS-CoV-2 is internalized through binding to ACE2 and cleavage by TMPRSS2.
d ACE2 gene expression in the lungs correlates with smoking, which is frequent in patients with cancer.
d TMPRSS2 gene expression in the prostate is androgen receptor dependent, but there are conflicting data on whether the
androgen receptor regulates TMPRSS2 in lung tissue.
d Androgen-targeted therapies, which are used in the treatment of prostate cancer, could limit SARS-CoV-2 infection by down-
regulating TMPRSS2 and/or stimulating an anti-SARS-CoV-2 immune response.
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The Structure of the SARS-CoV-2 Virus. SARS-CoV-2 is an en-
veloped, positive-sense, single-strand RNA virus and is part of
the Coronaviridae family (Andersen et al., 2020; Oberfeld et al.,
2020). Other viruses of the same family have been implicated
in bothmild seasonal illnesses and severe outbreaks, namely se-
vere acute respiratory syndrome coronavirus (SARS-CoV-1) and
Middle East respiratory syndrome coronavirus (MERS-CoV),
which caused the severe acute respiratory syndrome (SARS) in
2002 andMiddle East respiratory syndrome (MERS) in 2013 (An-
dersen et al., 2020; Oberfeld et al., 2020), respectively. SARS-
CoV-2’s envelope is made up of the Matrix (M) glycoprotein
and Envelope (E) protein and is coated by the Spike (S) protein
(Andersen et al., 2020; Oberfeld et al., 2020). SARS-CoV-2’s S
protein plays a key role in viral binding to host cells and internal-
ization: it has been shown to bind to the ACE2 surface receptor
of epithelial cells in the respiratory tree and is subsequently
cleaved by a host serine protease, Transmembrane Serine Pro-
tease 2 (TMPRSS2), to be internalized (Andersen et al., 2020;
Hoffmann et al., 2020; Oberfeld et al., 2020). Once the virus is
within an endocytic vesicle, other proteases, such as the host
cathepsin L (CTSL) protein, are thought to play a role in cleaving
the S protein to release the single-stranded RNA into the host
cell’s cytoplasm (Liu et al., 2020; Ou et al., 2020). Given that mul-
tiple host proteins have been suggested to play a key role in
SARS-CoV-2 infection, their expression patterns and the modu-
lators of their expression have been recently studied (Figure 1A).
Increased ACE2 Expression and Cancer. ACE2, or Angio-
tensin-Converting Enzyme 2, is a membrane-bound enzyme
that physiologically plays a role in maintaining blood pressure
homeostasis by cleaving angiotensin II (Keidar et al., 2007).
ACE2 expression in lung tissue, where it is thought to play a
key role in SARS-CoV-2 infection, has been suggested to in-
crease with age (Chen et al., 2020; Muus et al., 2020). Since pa-
tients with cancer are, on average, older than the general popu-
lation (Siegel et al., 2020), this has been proposed to be one of
the mechanisms mediating the particularly adverse clinical out-
comes observed in older patients. However, the relationship be-
tween age and ACE2 expression in lung tissue is disputed by
some other studies that have found either no relationship (Smith
et al., 2020a) or an inverse relationship (Booeshaghi and Pachter,
2020) between age and ACE2 expression in lung tissue. In addi-
tion, multiple studies have recently found that ACE2 expression
in lung tissue is increased in patients who smoke or who suffer
from smoking-related lung diseases such as chronic obstructive
pulmonary disease (Baratchian et al., 2020; Pinto et al., 2020;
Smith et al., 2020a). Moreover, there appears to be a dose-
response relationship between number of pack-years of smok-630 Cancer Cell 38, November 9, 2020ing and ACE2 expression (Smith et al., 2020a). Smokers are at
increased risk of various cancers, and especially lung cancer
(Siegel et al., 2020), and both lung cancer (Garassino et al.,
2020) and smoking (Kuderer et al., 2020) have been found to
especially correlate with adverse outcomes in patients with
COVID-19. It is therefore possible that these clinical findings
are, in part, mediated by the increased expression of ACE2 in
the lung tissue of smokers. The use of some anti-hypertensive
therapies, such as angiotensin II receptor blockers or angio-
tensin-converting enzyme (ACE) inhibitors, has also been found
to correlate with increased expression of ACE2 (Chung et al.,
2020). However, no relationship between the use of these agents
and the clinical outcomes of patients with COVID-19 has been
found (Chung et al., 2020).
TMPRSS2 Expression: Insights from the Field of Prostate Cancer
Research. TMPRSS2 is a membrane-bound serine protease
that has been studied in the context of prostate cancer, where
it has been shown to be highly expressed, and has been found
to be implicated in gene fusions with members of the ETS family
of transcription factors (particularly ERG) in up to 50% of primary
prostate cancers (Stopsack et al., 2020). TMPRSS2 expression
is modulated by the androgen receptor (AR) in normal prostate
tissue and prostate cancer (Lucas et al., 2014). Beyond prostate
tissue, it has been recently noted that TMPRSS2 is expressed in
lung tissue at the mRNA and protein levels (Stopsack
et al., 2020).
However, it is still unclear whether the regulation of TMPRSS2
expression in normal human lung cells is androgen dependent
(as it has been shown to be in prostate tissue). TMPRSS2 gene
expression has been found to be similar between males and fe-
males in normal lung tissue (Baratchian et al., 2020; Stopsack
et al., 2020), arguing against androgen-dependent regulation of
TMPRSS2 in lung tissue.Moreover, inmousemodels, TMPRSS2
gene and protein expression in lung tissue did not decrease
upon exposure to a potent AR antagonist, enzalutamide (Bar-
atchian et al., 2020). These findings contrasted with those of
other studies that found TMPRSS2 to be upregulated by testos-
terone treatment in a lung adenocarcinoma cell line (A549) and
that AR is a regulator of TMPRSS2 in these cell lines based on
chromatin immunoprecipitation assays (Mikkonen et al., 2010).
In addition, TMPRSS2 expression in lung tissue has been found
to correlate with the expression of androgen and estrogen-
related pathways ( Wang et al., 2020b), further suggesting that
TMPRSS2 may be regulated by AR.
Clinically, a retrospective population-based study from the
Veneto region in Italy reported that, although males generally
had worse outcomes when they developed COVID-19, patients
with prostate cancer who were treated by androgen deprivation
Figure 1. The Interplay between SARS-CoV-2 and Cancer Biology
(A) SARS-CoV-2 internalization.
(B) Immune interactions.
(C) Arterial and venous thrombotic events.
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Reviewtherapy (ADT) were less likely to be infected by SARS-CoV-2,
compared with patients with prostate cancer not on ADT and
with patients with other tumor types (Montopoli et al., 2020). In
parallel, another retrospective study from a cancer center in
the northeastern United States found that patients with prostate
cancer treated with ADT were less likely to develop adverse clin-
ical outcomes (hospitalization and oxygen supplementation),
compared with those not treated with ADT (Patel et al., 2020).
Randomized clinical trials that aim to evaluate the role of
androgen-targeted therapies for the treatment of COVID-19 are
currently ongoing. These clinical trials include those assessing
agents that are currently part of the standard of care of manage-
ment of prostate cancer, including AR antagonists such as bica-
lutamide (NCT04509999 and NCT04374279) and enzalutamide
(NCT04475601) as well as gonadotropin-releasing hormone an-
tagonists such as degarelix (NCT04397718).
Cancer, COVID-19, and the Immune System
There is evidence to suggest that the immune response to
SARS-CoV-2 can play differing roles (Figure 1B). Patients who
have certain forms of pre-existing primary or secondary immune
suppression appear to be at increased risk of severe outcomes
when they develop COVID-19 (Fung and Babik, 2020), high-
lighting the importance of an intact immune system in limiting
and responding to SARS-CoV-2 infection. Conversely, the se-
vere COVID-19 clinical syndrome, which develops in a subset
of patients and is characterized by respiratory failure or death,
has been attributed to a ‘‘cytokine storm’’ (Mangalmurti and
Hunter, 2020). Although not yet strictly defined by clinical or lab-
oratory criteria, this term has been used to refer to a hyperinflam-
matory state, biologically characterized by increased cytokine
levels and clinically by an acute respiratory distress syndrome-
like syndrome (Ackermann et al., 2020; Mangalmurti and Hunter,2020). Further evidence supporting the cytokine storm theory as
a cause for adverse outcomes in patients with COVID-19 comes
from the observation that patients with adverse outcomes of
COVID-19 appear to have increased levels of pro-inflammatory
cytokines, such as interleukin-6 (IL-6) (Cummings et al., 2020;
Lucas et al., 2020; Mo et al., 2020; Qin et al., 2020; Robilotti
et al., 2020;Wu et al., 2020), and the observation of a similar phe-
nomenon with previous coronavirus epidemics, SARS (Huang
et al., 2005) and MERS (Min et al., 2016). Of note, an alternative
hypothesis of the mechanism underlying the severe COVID-19
clinical syndrome has been termed a ‘‘bradykinin storm.’’ This
hypothesis is mainly based on analysis of RNA-sequencing
data from bronchoalveolar lavage samples showing that ACE
is downregulated while ACE2 is upregulated in patients with
COVID-19, comparedwith non-infected control patient samples.
Since ACE physiologically reduces bradykinin and ACE2 in-
creases bradykinin receptor-sensitizing peptides (angiotensin
1-9), these changes have been proposed to induce vasodilation,
vascular hyperpermeability, hyaluronic acid accumulation, and,
consequently, many of the clinical manifestations of severe
COVID-19 (Garvin et al., 2020). The ‘‘bradykinin storm’’ and
‘‘cytokine storm’’ hypotheses are also not entirely mutually
exclusive, since IL-2 has been found to be upregulated by brady-
kinin (Garvin et al., 2020).
In patients with cancer, immune system function can be either
suppressed or hyperactivated, because of the disease itself or
therapies used to treat it. Immune suppression is inherent to
many cancer types and the development of cancer itself is
thought to be, in part, due to a deficit in immune surveillance
(Swann and Smyth, 2007). Reversal of mechanisms of tumor im-
mune evasion has led to effective anti-cancer therapies, namely
immune checkpoint inhibitors (ICIs) (Sharma and Allison, 2015).Cancer Cell 38, November 9, 2020 631
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various infections due to neutropenia, lymphopenia, disruption
of anatomical surfaces (such as the nasal mucosa), splenic
and humoral defects, and the administration of cytotoxic or other
immune-suppressive therapies (Rolston, 2017; Safdar and Arm-
strong, 2011). This immune suppression could be one of the fac-
tors implicated in the increased risk of infection by SARS-CoV-2
of patients with cancer (Liang et al., 2020; Rogado et al., 2020).
Of particular interest to physicians is whether cytotoxic chemo-
therapy agents and targeted therapies could potentiate these
SARS-CoV-2-related risks and whether certain anti-cancer ther-
apies need to be withheld. The biological interactions between
the wide range of cancer-directed cytotoxic and targeted ther-
apy agents and the immune system are very diverse. These ef-
fects include immune suppression and stimulation (such as
through depletion of immune-regulatory cells) and depend on
the specificmechanism of action of each agent, as previously re-
viewed (Galluzzi et al., 2015). Therefore, as discussed in detail
from a clinical standpoint below, physician choices should be
guided by the emerging evidence of the safety of specific agents,
patient-specific treatment goals, and contemporaneous assess-
ment of the risk of SARS-CoV-2 infection (Schrag et al., 2020).
Cancer is also associated with a chronic pro-inflammatory
state, however, with activation of the innate immune system
(Coussens and Werb, 2002), and anti-cancer immunotherapies
have become part of the standard of care treatment of multiple
cancer types. These therapies, including ICIs, bispecific T cell
engagers (BiTEs), cytokine-based therapies, tumor-infiltrating
lymphocyte or chimeric antigen receptor T (CAR-T) cell therapy,
and allogeneic stem cell transplantation, lead to anti-cancer im-
mune responses but also stimulate a general immune response
that can affect normal healthy tissues, leading to immune-related
adverse events (Postow et al., 2018; Waldman et al., 2020).
These immune-related adverse events can include pneumonitis,
an often severe inflammation of the lungs (Postow et al., 2018).
Beyond the decrease in respiratory reserve that pneumonitis en-
tails, it is also the overlapping immune mechanisms of ICI-
induced pneumonitis and COVID-19 pneumonia that could
potentially increase the risk of immune-mediated lung damage
in patients treated by ICI and who develop COVID-19 (Acker-
mann et al., 2020; Reuss et al., 2020). In addition to the risk of
lung-specific immune-related adverse events, immunotherapies
pose the risk of systemic immune overactivation, which could
hypothetically potentiate cytokine release, given that many of
the same cytokines involved in ICI effectiveness also mediate
the cytokine storm, such as interferon gamma (IFN-g), tumor ne-
crosis factor alpha (TNF-a), granulocyte-macrophage colony
stimulating factor, and IL-2 (Berraondo et al., 2019; Chen and
Mellman, 2013; Mangalmurti and Hunter, 2020). This is espe-
cially true for CAR-T cell andBiTE therapy, a severe complication
of which is cytokine release syndrome, a syndrome that shares
many similarities with the cytokine storm associated with
COVID-19 (Shimabukuro-Vornhagen et al., 2018). The potential
for interaction between immune therapies and SARS-CoV-2
infection has been further suggested by the recent finding that
the expression of the receptor of this virus, ACE2, is upregulated
by IFN-g, a downstream effector of immune therapies (Ziegler
et al., 2020). Clinically, receipt of ICI therapy for cancer has
been associated with worse outcomes in patients with cancer632 Cancer Cell 38, November 9, 2020who develop COVID-19 in one cohort (Robilotti et al., 2020),
although the same relationship was not found in another study
(Lee et al., 2020a, 2020c).
The parallels between the mechanisms of immunotherapy-
related toxicities and the COVID-19 cytokine storm have led in-
vestigators to evaluate cancer immunotherapy-inspired thera-
peutic agents. In particular, tocilizumab, an anti-IL-6-receptor
antibody used in the treatment of BiTE- and CAR-T-induced
cytokine release syndrome (Le et al., 2018; Teachey et al.,
2013), has been evaluated for the management of COVID-19
(Guaraldi et al., 2020; Ip, 2020; Jordan et al., 2020; Price et al.,
2020; Somers et al., 2020), including in patients with cancer (Riv-
era et al., 2020). Although some of these retrospective studies
had suggested that a potential benefit was associated with toci-
lizumab in patients with COVID-19 (Guaraldi et al., 2020; Ip,
2020; Jordan et al., 2020), a recent randomized placebo-
controlled clinical trial evaluating tocilizumab, COVACTA
(NCT04320615), did notmeet its primary or secondary endpoints
(based on a press release) (Genentech Press Release, 2020).
Another anti-IL-6-receptor antibody, sarilumab, has also been
evaluated in a randomized placebo-controlled clinical trial
(NCT04315298), with a press release similarly reporting that it
did not meet its primary or secondary endpoints and with the trial
being discontinued in the United States (Regeneron Press
Release, 2020). Despite these disappointing results, IL-6 inhibi-
tors continue to be evaluated in clinical trials for the treatment
of COVID-19 (NCT04412772; NCT04409262). Other therapies
inspired by the care of patients with cancer have also been eval-
uated in patients with COVID-19. A single-arm, off-label, non-
randomized prospective study of 19 patients with severe
COVID-19 treated with acalabrutinib, a selective Bruton tyrosine
kinase (BTK) that is used in the treatment of lymphoid malig-
nancies, resulted in rapid improvement in oxygen requirements
in most patients and precipitous reduction in inflammatory
markers (including IL-6) (Roschewski et al., 2020). Randomized
clinical trials evaluating the treatment of patients with COVID-
19 with BTK inhibitors are currently ongoing (NCT04439006,
NCT04528667, NCT04346199). In a phase II randomized pla-
cebo-controlled clinical trial of 43 patients with severe COVID-
19, treatment with ruxolitinib, a JAK1/2 inhibitor used in the treat-
ment of myelofibrosis and polycythemia vera, tended to be asso-
ciatedwithmore rapid improvement of clinical, biologic (lympho-
penia), and radiographic features of COVID-19 (Cao et al., 2020).
The treatment of patients with COVID-19 with JAK inhibitors is
currently being evaluated in multiple randomized clinical trials
(NCT04477993, NCT04377620, NCT04390061, NCT04424056,
NCT04366232). Corticosteroids have wide-ranging immune-
suppressive functions that are believed to decrease the host im-
mune-mediated lung damage following SARS-CoV-2 infection.
These proposed benefits could be counterbalanced by the risk
that this immune suppression may diminish antiviral immune
response, as has been previously suggested with MERS-CoV
(Arabi et al., 2018) and SARS-CoV (Lee et al., 2004), and more
recently with SARS-CoV-2 (Westblade et al., 2020). Clinically,
dexamethasone, a corticosteroid widely used in many medical
applications, including in the treatment of cancer, was recently
found to decrease the mortality of patients with COVID-19 who
require respiratory support in a large randomized controlled trial
(RECOVERY, 2020a), establishing its role in this setting.
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with cancer, a population of patients with specific immune fea-
tures as outlined above, is not fully settled, because the RECOV-
ERY trial, which had established this benefit, did not specifically
report on the outcomes of patients with cancer. Given the im-
mune specificities of patients with cancer and their particularly
high risk of developing adverse outcomes with COVID-19, future
clinical trials should aim to specifically enroll and report on the
outcomes of patients with cancer.
SARS-CoV-2 and Cancer: A Perfect Storm for
Thrombosis?
COVID-19 has been found to be associated with significant
venous and thrombotic events (Figure 1C), with the relationship
termed COVID-19-associated coagulopathy (Connors and
Levy, 2020). Moreover, although the rate of symptomatic throm-
botic events has been found to vary between 9% and 21% (Klok
et al., 2020; Moll et al., 2020; Poissy et al., 2020), one study that
screened critically ill patients with COVID-19 using complete
duplex ultrasound found that 100% of those on prophylactic
anti-coagulation had venous thromboembolic events (VTEs)
compared with 56% of those on therapeutic anti-coagulation
(Llitjos et al., 2020). This propensity to develop thrombotic events
(including venous or, more rarely, arterial thromboses) appears
to be, at least in part, related to inflammation and the activation
of the innate immune system, which can activate systemic coag-
ulation pathways (Connors and Levy, 2020; Engelmann and
Massberg, 2013). In addition, endothelial cells also express the
ACE2 receptor (Ferrario et al., 2005), and viral inclusions have
been demonstrated in endothelial cells of patients with COVID-
19 (Varga et al., 2020), suggesting that viral endotheliopathy
and microcirculatory dysfunction can further contribute to the
thrombotic complications seen in patients with COVID-19.
Patients with cancer are particularly at risk of thrombotic com-
plications, since they have been found to have a 4- to 7-fold
increased risk of having VTEs compared with the general popu-
lation (Lee, 2003). This risk appears to vary by cancer type or
stage, receipt of local or systemic therapy, and the presence of
comorbidities (Falanga et al., 2013; Lee, 2003). The inherent
pro-coagulant state associated with cancer has been attributed
to the expression by cancer cells of coagulation factors impli-
cated in the extrinsic pathway of coagulation (such as tissue fac-
tor) and of pro-inflammatory factors (such as TNF-a and IL-1b)
(Falanga et al., 2013). Clinically, a single-center study evaluated
venous thromboembolisms in patients with cancer who devel-
oped COVID-19. Patients who developed VTEs had all been
admitted to the intensive care unit (ICU), with a cumulative inci-
dence of events of 9.3% of symptomatic VTE in ICU patients.
Most patients with symptomatic VTEs had developed these
events early in their disease course, suggesting that the ICU
stay was not a causative factor in these events but rather an in-
dicator of severe COVID-19 disease (Moll et al., 2020). In another
study comparing patients with active cancer with those without
cancer who developed COVID-19, patients with active cancer
did not have an increased risk of thrombotic events (arterial or
venous) (Patell et al., 2020). Despite the lack of clinical evidence
thus far of increased thrombotic events in patients with cancer in
small observational studies, the occurrence of occult thrombotic
events cannot be discounted as being one of the potential fac-
tors in the increased rate ofmortality due to COVID-19 in patientswith cancer (Garassino et al., 2020; Giannakoulis et al., 2020; Ku-
derer et al., 2020; Williamson et al., 2020), especially given the
strong prior evidence of a pro-coagulable state in patients with
cancer.
Defining and Identifying COVID-19 in Patients with
Cancer
Incidence and Prevalence
The incidence and prevalence of COVID-19 in patients with can-
cer continue to fluctuate as the pandemic unfolds, partially
related to differences in numbers of patients tested over time,
in line with distinct and changing local policies.
Early reports from China suggested that patients with cancer
might be at increased risk for infection (Liang et al., 2020; Yu
et al., 2020). For instance, data reported in January 2020 from
Wuhan, China, showed that, among patients hospitalized with
COVID-19 symptoms, 1%–2% had concomitant cancer diagno-
ses. This was higher than the overall incidence of cancer in the
general Chinese population (0.29%) (Liang et al., 2020). As the
pandemic spread, data from Italy reported in April 2020 showed
that, among patients with COVID-19 admitted to ICUs, 81 of
1,591 (8%) patients had active or prior malignancy (Grasselli
et al., 2020). Similarly, reports of patients with COVID-19 at
two large academic health care systems in New York showed
that 6%–7% of patients hospitalized with COVID-19 had active
cancer (Argenzian et al., 2020; Richardson et al., 2020).
Reasons for the documented elevated prevalence of COVID-
19 among patients with cancer may be due to biologic and
immunologic factors, discussed above, that predispose patients
to COVID-19. However, it is also possible that non-biologic fac-
tors may contribute to the relative increase in prevalence, for
example, the increased frequency of interfacing with the health
care system due to cancer treatment and surveillance, as well
as the close relationships that cancer patients have with health
care staff, perhaps leading to expedited testing in cancer pa-
tients with any symptoms.
Presentation and Outcomes
Based on symptomatology alone, the clinical presentation of
COVID-19 in patients with cancer does not differ compared
with patients without cancer. Patients generally experience fe-
ver, chills, myalgias, respiratory symptoms, sore throat, and/or
loss of taste or smell (Kuderer et al., 2020; Luo et al., 2020a,
2020b). Although the clinical spectrum of COVID-19 is heteroge-
neous, patients with active malignancy experience more severe
disease and higher observed death rates from COVID-19, which
have ranged between 5%and 61%,with a recentmeta-analysis-
based estimate of 25.6% (Dai et al., 2020; Giannakoulis et al.,
2020; Kuderer et al., 2020; Mehta et al., 2020; Saini et al., 2020).
Given the significant risk COVID-19 poses to patients with
cancer, pro-active strategies to improve early detection and
reduce the likelihood of infection have become top priorities for
health care institutions providing oncologic care. Several profes-
sional societies, including the American Society of Clinical
Oncology (ASCO) (ASCO, 2020a), the European Society for
Medical Oncology (ESMO) (ESMO, 2020), the Infectious Dis-
eases Society of America (IDSA, 2020), and the American Col-
lege of Surgeons (ACS, 2020a), among others, are pro-actively
engaged in issuing guidelines and practice recommendations
to help clinical practice.Cancer Cell 38, November 9, 2020 633
Box 2. Defining and Identifying COVID-19 in Patients with Cancer
d Patients initiating some anti-cancer therapy for the first time may be considered for testing for SARS-CoV-2 using nucleic acid
amplification for viral RNA (PCR).
d All patients undergoing cancer-directed therapy should be pre-screened using a standard questionnaire 48–72 h prior to sub-
sequent treatment cycles.
d If patients are positive on the pre-screen questionnaire, they should be referred for PCR testing prior to treatment.
d If the pre-screen is negative, they should be rescreened on the day of treatment and if not symptomatic and without known
exposure to COVID-19, they may be appropriate for treatment.
ll
ReviewTesting Procedures
The principle tenets involved in caring for and protecting vulner-
able patients with cancer during the COVID-19 pandemic
include implementation of robust screening and testing algo-
rithms for both patients and health care providers. In addition,
a focus on the physical environment, proper distancing, and per-
sonal protective equipment is a key issue in developing institu-
tional guidelines.
The two most widely used laboratory tests for SARS-CoV-2
include nucleic acid amplification tests (RT-PCR) and antibody
(serology) tests. The preferred testing method for screening
and diagnosis is the RT-PCR test, while the antibody-based
tests serve as supplemental tools for tracking immune response
(Tang et al., 2020). During the early days of the outbreak in China,
both oropharyngeal (OP) and nasopharyngeal (NP) swabs were
used for testing and diagnosis. However, the NP swab became
preferred after data showed that SARS-CoV-2 RNA detection
was 32% in OP swabs compared with 63% in NP swabs
(Wang et al., 2020a). The NP swab is the primary test currently
used in screening algorithms for patients and health care em-
ployees. Although the NP RT-PCR test is sensitive, specific,
and able to be processed in large batches of samples, the turn-
around time can be on the order of weeks. A point-of-care test,
with results available in minutes, could change the nature of the
pandemic with respect to clinical care and political mandates
(Wolters et al., 2020).
The ASCO guidance on cancer care delivery during the
COVID-19 pandemic, discussed below, is based on recommen-
dations from the IDSA and is particularly helpful regarding the
procedure for implementing a pre-screening and screening pro-
gram in the ambulatory setting (ASCO, 2020b). In all cases of
symptomatic patients, whether in hospital or in an ambulatory
setting, the recommendation is to test (Box 2). Similarly, all pa-
tients who are initiating treatment with cytotoxic chemotherapy,
stem cell transplantation, long-acting biologic therapy, cellular
immunotherapy, or high-dose corticosteroids for the first time
should be considered for testing 48–72 h before initiation of ther-
apy, although this is not an international recommendation. Pa-
tients should be pre-screened 48–72 h prior to subsequent cy-
cles using a standardized questionnaire addressing symptoms
and potential exposure. If patients have history of COVID-19
exposure, respiratory symptoms, or two other symptoms
(cough, shortness of breath, fever, chills, myalgias, sore throat,
new loss of taste or smell, or other flu-like symptoms), they
should be triaged to testing. It is recommended to have testing
performed at a site other than the cancer care facility, if able,
to avoid bringing positive cases into cancer treatment facilities.634 Cancer Cell 38, November 9, 2020If patients have a negative pre-screen, defined by lack of symp-
toms and no close or proximate contact with anyone who tests
positive for COVID-19, they should present for care on the
planned treatment day. Upon arrival at the health care facility,
patients should again be screened to determine if there has
been a change in status and/or need for testing or retesting.
In a few cases, asymptomatic chronic carriers have been iden-
tified. In this situation, data suggest that it is best to observe for a
period of time and monitor for COVID-19 symptomatology prior
to administering treatment. Recent analysis of test results from
asymptomatic patients (1,988 tests from 1,226 patients) under-
going chemotherapy from the UK Birmingham Chemotherapy
Cancer COVID-19 cohort revealed that the asymptomatic prev-
alence is 0.6% (Lee et al., 2020b). Follow-up data on rates of
symptomatic disease are not currently available. Although a
smaller analysis, data from a universal pre-chemotherapy testing
program at a hospital in Dubai, United Arab Emirates, revealed
that 7 of 85 asymptomatic patients with cancer were positive
by PCR screening (8.2%; 95% CI 2.4%–14.1%), all of whom
subsequently developed symptomatic disease (Al-Shamsi
et al., 2020). It should also be noted that the rates of asymptom-
atic carriage are directly linked to the rate of infection where
studies are performed. These data highlight the principle of early
detection of pre-symptomatic patients and risk mitigation with
COVID-19 in the context of cytotoxic and myelosuppressive or
immunomodulatory treatments.
If a patient has a positive test result, an immediate treatment
break or delay is warranted. However, some patients may still
be able to receive treatment if they are on low-risk regimens, if dis-
ease burden mandates undertaking such a risk, and provided
there is a designated COVID-19 treatment area or linear acceler-
ator with dedicated staff in place. When or if to restart treatment
after a positive test result is not clearly definedbypublished guide-
lines. However, expert consensus in line with ASCO guidelines is
anchored on consideration of the context of medical necessity.
Some providers may retest to ensure two successive negative
PCR tests a minimum of 24 h apart, unless testing is unavailable
or not required by local guidelines; however, long-term shedding
does occur and highlights the necessity of using clinical context
and judgment. Indeed, in addition, and often exclusively, both
criteria of a complete clinical recovery of at least 10–14 days since
symptom onset, without fever or significant symptoms for at least
48–72 h, are mandated. Available data suggest that, once symp-
toms have resolved, persistent viral shedding can be observed for
up to 66 days, leading to positive PCR tests after recovery that
may not represent infectiousness; but this is an area of ongoing
investigation (Agarwal et al., 2020; Bullard et al., 2020).
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Equipment
In the COVID-19 era, the physical spaces of health care centers
have been transformed by intentional focus on crowd control
and flow of people. It is quite common for institutions to have a
single point of entry equipped with triage stations and testing ca-
pabilities. Physical distancing (6 ft, 2 m) is encouraged andmain-
tained, appointment times are staggered, and hours of operation
are extended to decrease the number of patients in waiting
rooms. Most elevators now have ‘‘dots’’ on the floor indicating
where people are supposed to stand to prevent overcrowding.
All employees and patients are required to wear medical-grade
face masks, when in facilities, or N95 respirators, if patients
are confirmed positive or suspected of having COVID-19. Early
on during the pandemic, health care centers often limited care-
givers and other family members from accompanying patients
on visits, which brought particular challenges to patients with
cancer diagnoses. These policies are often dependent on each
state’s mandates, phase of recovery, and local and regional
case load.
Planning for and ensuring a robust supply chain and inventory
of personal protective equipment (PPE) are essential to all health
care centers as the pandemic continues. Data from a survey of
343 oncologists from 28 countries with a self-reported COVID-
19 outbreak (99.7%) reported that PPE was available to all par-
ticipants (Ür€un et al., 2020). It should be noted that the type of
PPE used by the participating oncologists varied, and while
89.8% reported using surgical face masks, only 39.7% and
32.4% reported using eye goggles/glasses and N95 masks,
respectively. Moreover, the responses to the survey were re-
corded between April 1 and April 29, 2020, during which time
the incidence of COVID-19 infection varied widely across the
geographically diverse respondents to the survey. Therefore,
although this survey is somewhat reassuring in that it shows
that oncologists had some degree of PPE available during the
pandemic, its results should be noted with caution given the di-
versity in the type of PPE that was used by the responding oncol-
ogists and the fact that the survey responses may have not been
recorded during the peaks of the pandemic in the respective
geographic regions, when PPE would be most at risk of being
scarcely available.
Optimization of reuse and of filtering facepiece respirators, re-
turn-to-work policies for infected health care professionals,
work-from-home policies, attention to stress management, and
providing mental health resources are all additional components
of an effective cancer care delivery model during the COVID-19
pandemic.
Changes in Cancer Care Delivery
In addition to the drastic changes to everyday life, the COVID-19
pandemic poses unique challenges to the delivery of oncologic
care and is forcing us to redefine cancer care delivery models.
Key to clinical practice changes is adapting to the specific sce-
nario in which each community exists over time (Harky et al.,
2020). Practice patterns will continue to evolve as the locore-
gional case volume and phases of reopening ebb and flow.
Telehealth
Telehealth has come to the forefront of clinical care during the
COVID-19 pandemic. Although it may not be right for every pa-tient and every situation, such as goals of care discussions, it
provides a safe and easy way for patients to access their doctors
at a time when human contact and mobility present substantial
health risks due to the high transmissibility of the SARS-CoV-
2 virus.
On March 30, 2020, the US Centers for Medicare & Medicaid
Services (CMS) issued the 1135 waiver, loosening regulations
and allowing for expansion of coverage for telehealth services
to Medicare beneficiaries. Although some centers had been
early adopters of telehealth in the pre-COVID era to fill gaps in
care that resulted from provider shortages, after the 1135 waiver
was issued, nearly all centers reconfigured care delivery models,
focusing on the expansion of telehealth capabilities (Royce et al.,
2020). The CMS issued further clarification detailing regulatory
changes, including lifting of telehealth restrictions on urban
areas, new patient visits, HIPAA regulations, remote supervision
of services rendered, and supervision of resident physicians
(Royce et al., 2020). Perhaps most importantly, CMS clarified
that telehealth services paid under the Physician Fee Schedule
are the same as in-person services (CMS, 2020). Although these
regulations apply toMedicare beneficiaries, many private payers
and state Medicaid programs have announced expanded
coverage as well. Despite these relaxed policies, challenges
remain. For example, a telehealth appointment where the patient
is physically in another state from the clinician is considered to
cross state lines, and the clinician must have an active license
in the state where the patient resides. Emergency licenses
have been granted, but whether these programs will continue
is unclear (Hollander and Carr, 2020). At a global level, telehealth
may impose billing and reimbursement barriers, in addition to a
significantly different organization of work, as well legal context.
The degree to which telehealth may affect quality and out-
comes in cancer care is still being defined. One can look back
to data from the pre-COVID era, which in a brief prepared for
the Agency for Healthcare Research and Quality showed evi-
dence of the effectiveness of remote monitoring of patients,
communication and counseling for patients with chronic condi-
tions, and providing behavioral support and psychotherapy
(Tuckson et al., 2017). Furthermore, a Cochrane systematic re-
view of 93 trials (N = 22,047 participants) evaluated the effective-
ness of telehealth as an additive, alternative, or comparison to
usual care across several clinical conditions. This review found
no difference in all-cause mortality (Flodgren et al., 2015). In
fact, the study found an increase in quality of life for those allo-
cated to telehealth compared with usual care and improved dis-
ease control in diabetes, hypercholesterolemia, and hyperten-
sion. From the oncologic side, results from a meta-analysis of
20 randomized-controlled trials that assessed the effect of tele-
health intervention versus usual care in patients with breast can-
cer showed that telehealth was associated with a higher quality
of life and self-efficacy, and less depression and distress,
compared with usual care (Chen et al., 2018). Specific to the
COVID-19 pandemic, additional advantages of telehealth
include reducing PPE demands, limiting exposure, and reducing
travel and wait times for patients.
Appropriate patient selection for telehealth oncologic care,
however, is key. Both ESMO (ESMO, 2020) and ASCO (ASCO,
2020a) suggest that patients not requiring an in-person exam,
treatment, or diagnostics should have telehealth visits duringCancer Cell 38, November 9, 2020 635
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appropriate if the primary reason for the clinic encounter is to
follow up on treatment adherence for oral agents, survivorship,
genetic counseling, supportive services, or education. Imple-
mentation guides and toolkits are published to assist with the
rapid integration of outpatient telehealth programs (Smith
et al., 2020b).
It is also important to consider the unintended consequences
of widespread adoption of technology. There is a serious poten-
tial risk of compounding health disparities between patients of
different socioeconomic status if telehealth services are
mandated. This has been recently highlighted by a multicenter
prospective cohort study showing that, among patients with
cancer in the northeastern United States, Black andHispanic pa-
tients were less likely to benefit from telehealth visits, compared
with White patients (Doroshow et al., 2020). Care should there-
fore be taken to assess tech literacy and digital services before
scheduling services (Elkaddoum et al., 2020), and health care
professionals should attempt to minimize disparities in the use
of telehealth by evaluating the barriers to adoption.
Screening andDiagnosis during theCOVID-19Pandemic
Global interruptions to cancer screening began with national and
state lockdowns. Many patients, providers, and health care insti-
tutions temporarily suspended routine cancer screening and
diagnostic procedures until the appropriate provisions and
safety measures (institutional protocols, testing capabilities,
and PPE inventory) were in place. As a result, routine screening
dropped by asmuch as 85%–90% (London et al., 2020). Now, as
some health care centers inch toward a new normal, many are
struggling with management of the backlog of cases. In the
United Kingdom, for example, it is estimated that 1million people
have not been invited to colorectal cancer screening and
approximately 8,500 people who received a positive fecal immu-
nochemical test by mail before the national lockdown are
currently awaiting an appointment for a follow-up colonoscopy
(The Lancet Gastroenterology & Hepatology, 2020). Based on
the importance of early screening and detection, combined
with the effects of treatment delays, it is perceived, but not char-
acterized, that delays in diagnosis during the pandemic may
negatively affect cancer outcomes.
In a population-based modeling study from the United
Kingdom assessing the impact of diagnostic delays on survival
in breast, colorectal, esophageal, and lung cancer, substantial
increases in the number of avoidable cancer deaths are ex-
pected to result. In this model, the increase in deaths 5 years af-
ter initial diagnosis may be 4%–17%higher, depending on tumor
type, due to diagnostic delays during the COVID-19 pandemic
compared with pre-pandemic figures (Maringe et al., 2020).
Similarly, in another observational modeling study from the
United Kingdom, delays of 3–6 months in surgery for incident
cancers would decrease life years gained by said surgery by
19% and 43%, respectively, and 26% and 59% when consid-
ering resource-adjusted life years gained (Sud et al., 2020).
ASCO (ASCO, 2020a) and ESMO (ESMO, 2020) guidelines
recommend that cancer care screening services, including colo-
noscopies, pap smears, and mammograms, resume in accor-
dance with state and local health authorities. Expanding existing
capacity as rapidly as possible should be at the forefront of can-
cer care delivery systems’ efforts.636 Cancer Cell 38, November 9, 2020Cancer-Directed Therapy during the COVID-19
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Surgical Oncology. During peak numbers of COVID-19 cases
in a community, nearly all non-urgent or ‘‘elective’’ surgeries
have been delayed, as reported in studies from the M.D. Ander-
son Cancer Center (Chang and Liu, 2020) and the University of
Alabama-Birmingham (Morrison et al., 2020). The impact on
future cancer progression and death as a result of current delays
in ‘‘elective’’ cancer surgeries are not yet known. However, in-
vestigators from England used hazard ratios from observational
studies from 2013 to 2017 to model cancer progression and loss
of life years due to surgical delays. They estimated that a 3- or 6-
month delay of surgery across all stage 1–3 cancers would cause
4,755 and 10,760 deaths, respectively, among the 94,912 pa-
tients undergoing resections for major cancers per year (Sud
et al., 2020). For now, many surgical oncologists and multidisci-
plinary treatment teams are focused on prioritizing surgeries
based on clinical rationale, and potential alternative non-surgical
management strategies, with decisions being based on locally
available resources in line with the American College of Sur-
geons ‘‘Roadmap for Maintaining Essential Surgery during
COVID-19 Pandemic’’ (ACS, 2020b).
Systemic Therapy. Decisions regarding the use of systemic
therapy during COVID-19 should be guided by routine oncology
care and characteristics of systemic treatment on the immune
system. Conversations with patients and shared decisions
should focus on evidence-based incremental benefits with the
proposed treatment versus the risk of contracting COVID-19
while coming to the clinic for cancer-directed therapy (Gharzai
et al., 2020). As outlined by Schrag and colleagues, oncologic
treatment generally falls into four categories, those with: (1) cura-
tive potential, (2) moderate clinical importance, (3) marginal
impact on quality or quantity of life, and (4) survivorship and sur-
veillance (Schrag et al., 2020). Cancer-directed therapy that has
curative potential, or dramatic improvements in outcomes,
should not be delayed. Treatments indicated for patients in the
survivorship and surveillance stagemost likely can be continued,
given that oral chemotherapy and hormonal therapy can
commonly be monitored remotely and require less frequent
blood work and in-person visits. However, when the incremental
benefit of systemic treatment may be marginal, clinical decision-
making is not as clear cut. Considerable uncertainty relative to
risks and benefits with each treatment and prevalence of
COVID-19 in the local setting are variables in the conversation.
Radiation Therapy. Radiation therapy, a prominent pillar in can-
cer care given its often curative and palliative role, has similarly
been affected by the COVID-19 pandemic. The American Soci-
ety for Radiation Oncology (ASTRO) surveyed a wide variety of
US radiation oncology community and academic practices to
assess the initial impact and operational responses to the
COVID-19 pandemic. All practices reported uninterrupted oper-
ation; however, on average the typical volume had decreased to
68% (range, 10%–95%). Treatment delays were reported by
92% of practices, with the most delays of treatment for low-
risk prostate (88%) and early-stage breast cancer (73%). How-
ever, the treatment of more aggressive tumor types (such as
gastrointestinal, central nervous system, and small cell lung can-
cers) was delayed by less than 15% of practices, suggesting the
safety and importance of providing this essential and non-
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from China and Italy showed that very few patients required
treatment interruptions in radiotherapy services, and few pa-
tients undergoing radiotherapy were diagnosed with COVID-19
during their treatment course (0.48%, 1 of 209 patients) (Krengli
et al., 2020; Xie et al., 2020). As per ASTRO’s ‘‘COVID-19 Clinical
Guidance Resources,’’ it is imperative that services are provided
with robust prevention and that infection control measures be
put in place (ASTRO, 2020).
Effect of the COVID-19 Pandemic on Oncologic Clinical Trials.
Cancer clinical trials have also been critically affected by the
pandemic, with outright halting of all enrollment at some centers
during the peak case volume. A cohort study assessing the ef-
fects of the pandemic on national enrollment in cancer clinical tri-
als conducted by the SWOG Cancer Research Network showed
a decrease in enrollment from 125 to 150 patient enrollments per
week in early January (week 1) to 74 enrollments per week near
the end of the study period (week 17) (Unger et al., 2020). In
March 2020, ASCO surveyed 64 investigators at academic and
community practices on the conduct of clinical trials during the
COVID-19 pandemic. Nearly 60% of respondents’ programs re-
ported halting screening and/or enrollment for certain trials, 50%
of respondents’ programs ceased research-only blood and/or
tissue collections, and 65.6% of site initiation visits were con-
ducted remotely (Waterhouse et al., 2020). In addition, tier-
based approaches to prioritizing trials were utilized at 53.1% of
respondents’ programs. Challenges noted to continuing clinical
trial investigations during the pandemic include patients’ inability
to return to health care centers for study visits, especially if they
are traveling from outside the state and have quarantine mea-
sures to abide by; the limited availability of ancillary services;
and the challenge of holding timely discussions with sponsors
and contract research organizations. However, as noted by
Waterhouse and co-workers, some positive clinical trial-related
lessons are worth perpetuating forward to the post-COVID era.
Trialists should continue to streamline visits and create more
flexible study timelines, leverage telehealth to limit in-person
visits, and use e-signatures for trial documentation (Waterhouse
et al., 2020), while trial sponsors should continue to demonstrate
increased flexibility with regard to trial protocols. This opportu-
nity to reform how we conduct clinical trials moving forward rep-
resents potential areas of improvement for the future (Nabhan
et al., 2020). For instance, incorporating telehealth visits and
remote consent routinely into clinical trials, as has been done
during the pandemic for some clinical trials (Li et al., 2020), could
help render trials more accessible and, consequently, trial pa-
tient populations more representative of real-world patient pop-
ulations. Crucially, a recently reported experience from the
Dana-Farber Cancer Institute demonstrates that the incorpora-
tion of telemedicine and mailing of oral investigational agents
during the pandemic was not associated with increases in
serious adverse events or major violations related to drug dosing
(Tolaney et al., 2020).
The RECOVERY trial, while evaluating COVID-19-directed
therapies and not cancer-directed treatments, is a striking
example of how randomized controlled trials can be conducted
efficiently, cheaply, and collaboratively when regulatory require-
ments are relaxed and clinical trial protocols are simplified (Ema-
nuel et al., 2020). This trial has thus far shown that dexametha-sone is effective in the treatment of patients with COVID-19
who require respiratory support (RECOVERY, 2020a), and that
the lopinavir-ritonavir combination (RECOVERY, 2020b) and hy-
droxychloroquine (Horby et al., 2020) are not effective in the
treatment of COVID-19.
There are ongoing large national and international efforts to
characterize and understand the impact of the COVID-19
pandemic within the oncologic community. The ASCO Registry
is one such survey designed to collect baseline and follow-up
data on how the virus affects cancer care and the outcomes of
patients with cancer (ASCO, 2020c). Measuring the effects of
lower clinical trial recruitment and results on drug development
plans in the pharmaceutical industry space will be important to
characterize.
Clinical Factors, Biomarkers, and Prognostic Models:
Which Patients with Cancer Are Most at Risk?
Although patients with cancer are now recognized to be at
increased risk of adverse outcomes with COVID-19 (Garassino
et al., 2020; Giannakoulis et al., 2020; Kuderer et al., 2020; Wil-
liamson et al., 2020), this patient population is large and relatively
heterogeneous. Identifying patients that are at particularly
increased risk is essential for risk stratification, tailoring preven-
tion measures, and cancer and COVID-19 treatment. As such,
multiple studies have attempted to determine prognostic factors
in patients with COVID-19 in general, or specifically within the
subgroup of patients with pre-existing diagnoses of cancer (Ta-
ble 1; Box 3).
Clinical Factors
Tumor Type, Active Cancer, and Stage. Tumor-related factors
appear to be a significant prognostic factor in patients with can-
cer. In particular, certain tumor types have been found to be
associated with particularly poor outcomes with COVID-19.
These include lung cancer (Dai et al., 2020; Garassino et al.,
2020), potentially due to reduced respiratory reserve, and hema-
tological cancers (Dai et al., 2020; He et al., 2020; Kuderer et al.,
2020; Lee et al., 2020a, 2020c; Passamonti et al., 2020; William-
son et al., 2020), perhaps due to the inherent immune suppres-
sion that is associated with the cancer itself and the more im-
mune-suppressive therapeutic regimens that are often used to
treat these cancers (Rubinstein and Warner, 2020).
Beyond the type of cancer, it is also the status of the tumor
(active, stable or progressing, or in remission) that seems to influ-
ence the prognosis of patients with cancer who develop COVID-
19. Patients with advanced cancer as well as progressing dis-
eases have been consistently found to have worse outcomes
(compared with those with localized disease or who are in remis-
sion) (Albiges et al., 2020; Dai et al., 2020; Kuderer et al., 2020;
Passamonti et al., 2020; Pinato et al., 2020; Tian et al., 2020). It
is thus far unclear whether this association is due to the general
poorer health status of patients with more advanced cancer dis-
ease, affecting treatment strategies adopted while driven by the
cancer prognosis (e.g., earlier referral to comfort-based care), or
whether advanced or progressing cancers affect the COVID-19
disease course due to intersecting biological mechanisms with
SARS-CoV-2, as discussed above.
Receipt of Systemic Cancer-Targeted Therapy. As discussed
above, some general guiding principles have emerged with re-
gard to systemic cancer-targeted therapies (Schrag et al.,Cancer Cell 38, November 9, 2020 637
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surgery)
Increasing age x x x x x x x x
Male sex x x x
Comorbidities x x x x
ECOG PS x x x
Smoking x x x
CCC19, COVID-19 and Cancer Consortium; ICI, immune checkpoint inhibitor; PS, performance status; TERAVOLT, Thoracic Cancers International Covid 19 Collaboration; UKCCMP, UK Corona-



































Box 3. Which Patients with Cancer Are Most at Risk?
d Lung cancer and hematologic cancers and advanced or active cancers are associated with adverse outcomes upon SARS-
CoV-2 infection.
d There are currently conflicting data on the relationship between receipt of systemic anti-cancer therapies and COVID-19 out-
comes in patients with cancer.
d Certain factors found to be associated with adverse outcomes in the general population were also associated with poor out-
comes in patients with cancer, including male sex, increasing age, comorbidities, poor performance status, and smoking.
d In patients with cancer who develop COVID-19, markers of inflammation (IL-6, TNF-a), of organ damage (decreased albumin-
globulin ratio and increased NT-proBNP), and of immune dysfunction (decreased lymphocytes and CD4+ T cells) were asso-
ciated with adverse prognosis.
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particularly low-value systemic therapies can be deferred; data
are still needed to assess the risk-benefit ratio of specific sys-
temic therapies in the midst of the pandemic. Data on the rela-
tionship between specific systemic therapies and COVID-19
outcomes have been sparse thus far, mostly because of the het-
erogeneity of systemic therapy regimens, the timing of receipt of
systemic therapy relative to COVID-19 diagnosis, the presence
of multiple possible confounding factors (such as by indication
and due to cancer type), and the relatively small numbers of pa-
tients on specific regimens who develop COVID-19.
There are currently conflicting data on the association be-
tween receipt of systemic therapy and prognosis. In particular,
receipt of ICIs (Robilotti et al., 2020; Tian et al., 2020) and chemo-
therapy (Albiges et al., 2020; Lee et al., 2020a, 2020c) was asso-
ciatedwith poor outcomes in patients with cancer andCOVID-19
in some studies, but other studies had reported no association
(Kuderer et al., 2020; Lee et al., 2020a, 2020c; Luo et al.,
2020a, 2020b; Passamonti et al., 2020). However, it should be
noted that the absence of conclusive evidence of the association
between receipt of systemic therapy and adverse COVID-19 out-
comes should not be taken for evidence of absence of an effect.
In particular, each of these studies is likely powered only to
detect relatively large effects and groups systemic therapies
into groups of therapies with related mechanisms of action.
The effects of less frequently used systemic therapies (such as
experimental therapies and specific combination regimens) are
thus far largely unexplored. Moreover, the potential for interac-
tion between systemic therapy regimens and cancers that pre-
dispose to worse COVID-19 outcomes (such as hematologic
and lung cancers) has also not been evaluated. Therefore,
caution should prevail when treating patients with cancer during
periods of COVID-19 resurgence, and the benefits and risks of
each therapy should be weighed during consultations with pa-
tients (Schrag et al., 2020).
Social Determinants of Health. Although the pandemic has, at
the time of this writing, hit most countries in the world, patient
populations have been unevenly affected, even within the
same country or geographic region. In particular, in the United
States and in the United Kingdom, race and ethnicity have ap-
peared to be important correlates of rates of infection and of
adverse outcomes in patients with COVID-19 in general (Chowk-
wanyun and Reed, 2020; Williamson et al., 2020; Yancy, 2020).
This result mirrors the relationship previously observed between
adverse outcomes in other diseases, including cancer, and raceand ethnicity (Badal et al., 2020; Marinac et al., 2020; Marinaro
et al., 2020; Yedjou et al., 2019). These health disparities are
thought to be largely driven by socioeconomic status, lack of suf-
ficient access to care, and area of residence, but biological fac-
tors have been implicated in certain instances (although not with
COVID-19).
Whether health disparities are also pronounced in patients
with cancer who develop COVID-19 has not been fully estab-
lished. However, it seems plausible that this relationship, be-
tween being part of racial or ethnic minorities and adverse
COVID-19 outcomes, would hold or even be more pronounced
in patients with cancer. In fact, there are early signals to this ef-
fect from certain studies of patients with cancer and COVID-19,
with one study suggesting that Black patients with cancer are
half as likely to receive remdesivir for COVID-19 compared
withWhite patients (Rivera et al., 2020). Furthermore, others sug-
gest that health disparities with regard to cancer care are more
likely to become accentuated during the COVID-19 crisis due
to socioeconomic factors and decreased access to telehealth
services (Balogun et al., 2020).
Comorbidities and General Factors. Beyond cancer-specific,
cancer treatment-related, and demographic factors, other gen-
eral patient factors seem to be important correlates of prognosis
for patients with cancer who develop COVID-19. Similar to the
general population of patients with COVID-19, the following fac-
tors all correlated with poor prognosis in patients with cancer:
male sex (Kuderer et al., 2020; Lee et al., 2020a, 2020c; Pinato
et al., 2020), older age (Albiges et al., 2020; Garassino et al.,
2020; Kuderer et al., 2020; Lee et al., 2020a, 2020c; Passamonti
et al., 2020; Pinato et al., 2020; Robilotti et al., 2020; Tian et al.,
2020; Westblade et al., 2020), comorbidities (including cardio-
vascular and respiratory) (Garassino et al., 2020; Kuderer et al.,
2020; Lee et al., 2020a, 2020c; Pinato et al., 2020), smoking (Al-
biges et al., 2020; Garassino et al., 2020; Kuderer et al., 2020;
Luo et al., 2020a, 2020b), and poor general performance status
(Albiges et al., 2020; Kuderer et al., 2020; Tian et al., 2020).
Many of these factors are associated with cancer itself and this
may account for the generally poorer prognosis of patients
with cancer who develop COVID-19.
Biomarkers of Adverse Prognosis
In addition to clinical factors, prediction of outcomes of patients
who develop COVID-19 could be refined by including bio-
markers or laboratory results. For instance, a recent study has
found that increased IL-6 and TNF-a, which are both thought
to be involved in the COVID-19 cytokine storm, can predictCancer Cell 38, November 9, 2020 639
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other clinical factors (Del Valle et al., 2020). Other potential bio-
markers have included neutrophil count, lymphocyte count, C-
reactive protein level, platelet count, and creatinine, among
others (Wynants et al., 2020).
These findings have been corroborated in patients with can-
cer, whereby inflammation markers (increased in IL-6, TNF-a,
C-reactive protein, procalcitonin, ferritin, and D-dimer) (Albiges
et al., 2020; Tian et al., 2020), markers of organ damage
(decreased albumin, increased cardiac enzymes and lactate de-
hydrogenase) (Albiges et al., 2020; Tian et al., 2020), andmarkers
of immune dysfunction (decreased lymphocytes, monocytes,
and CD4+ T cells) (Albiges et al., 2020; Tian et al., 2020) have
all been associated with adverse prognosis. In addition to pa-
tient-specific biomarkers, increased SARS-CoV-2 viral load
has been recently found to be a predictor of adverse prognosis
in patients with or without cancer (Westblade et al., 2020).
Prognostic Models and Collaboration
Whereas these correlates of prognosis are important to inform
clinical practice, developing prediction models that accurately
predict patient outcomes and that are usable in clinical practice
could help triage patients, focus resource utilization, and serve
as stratification factors in clinical trials. Unfortunately, a recent
review of predictive models for patients with COVID-19 in gen-
eral concluded that despite the fact that a multitude of models
have so far been published, none are currently usable in clinical
practice (Wynants et al., 2020), largely due to insufficient report-
ing and high risk of bias.
In particular, patients with cancer form a relatively small pro-
portion of the overall number of patients infected with COVID-
19, and multiple studies have not specifically reported on
whether the patients included had a cancer diagnosis. This rai-
ses concerns with regard to the generalizability of existing
models to patients with cancer. Developing predictive models640 Cancer Cell 38, November 9, 2020that are specific to patients with cancer or validating existing
models in patients with cancer will require multi-institutional col-
laborations to ensure adequate statistical power and generaliz-
ability. Fortunately, multiple multi-institutional initiatives are
currently working on aggregating data on patients with cancer,
including the COVID-19 and Cancer Consortium (CCC19) (Ru-
binstein et al., 2020), ESMOCoCARE, Thoracic Cancers Interna-
tional Covid 19 Collaboration (TERAVOLT) (Whisenant et al.,
2020), the UK Coronavirus Cancer-Monitoring Project (Anil
et al., 2020), and others, as previously described (Desai et al.,
2020; Palmieri et al., 2020).
Impact of COVID-19 on Cancer Research
Funding
The effects of the COVID-19 pandemic are wide ranging. In addi-
tion to its impact on patients and providers, cancer researchers
have also had their routine research lives upended. As noted in a
letter from the American Association for Cancer Research direc-
tors to the US Congress (AACR, 2020), many researchers admi-
rably contributed to the global and national interest by repurpos-
ing their cancer research labs to help address the needs of
combating the pandemic (Figure 2). Their labs and facilities
helped develop novel tests, aided in drug screens, conducted
vaccine research, and analyzed population cohort data. This
shift in research focus has been made possible by increased
flexibility in federal grant mechanisms. Specifically, the National
Institutes of Health offeredUrgent and Emergency competing re-
visions and administrative supplements to existing grant awards
on a rolling basis. When COVID-19 research is proposed, it is
considered as ‘‘in (or out) of the scope’’ of the parent grant,
with a broad interpretation of ‘‘in the scope,’’ because virtually
no NCI grantees have COVID-19 grants (Singer, 2020). Although
the federal government is able to support ongoing research due
to appropriations, not all funding sources are as flush. COVID-19
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giving organizations. As such, prominent organizations such as
the American Cancer Society (ACS) have not been able to accept
award applications for the fall grant cycle due to the financial
impact of the pandemic on philanthropy. The ACS expects to
experience a $200 million decrease in philanthropic donations
during 2020. This represents an approximately 25% decrease
in donations relative to the pre-COVID era. Typically, 12%–
14% of donations are ear-marked for supporting extramural
research (i.e., research that is separate from intramural research
activities). ACS funded $37 million worth of extramural research
during the pandemic, down from the typical $45–55 million over
the same time span in the pre-COVID era. The funding that is
currently available is being directed toward Cancer Research
Scholar grants that target early-stage investigators and Mission
Boost grants that target translation to patients, according to the
chief medical and scientific officer, Dr. William Cance (personal
communication, September 2020). The ACS is also not alone
in having to decrease funding for cancer research, with the Ca-
nadian Institutes of Health Research and Cancer Research UK
undertaking similar measures (Webster, 2020). The impact on
cancer research funding is therefore likely to be felt globally,
with governments and philanthropic organizations around the
world having to take similar measures due to the unforeseen
challenges posed by the pandemic.
Science, Home, and Human Interactions
In addition to the shift in focus of laboratory-based research
and the effects on funding, cancer researchers have had their
scientific investigation, home life, and professional interac-
tions uprooted. In many cases, the ability to perform experi-
ments was altogether halted as institutions and labs were
shut down entirely (Colbert et al., 2020). Reopening is largely
dependent on local benchmarks and institutional prepared-
ness. After state and local mandates to shelter in place were
invoked, many researchers were additionally faced with duties
such as caring for family members and home-schooling chil-
dren. Although this change in work-from-home conditions
was universal, using academic metrics to determine whether
certain populations have been disproportionately affected
(i.e., parents of school-aged children, women, members of un-
derrepresented minority groups, urban versus rural col-
leagues, earlycareer versus mid-career versus established in-
vestigators) will be informative. Levine and Rathmell write in a
call-to-action editorial (to support early-career investigators)
that ‘‘reduced productivity during this time (pandemic clo-
sures) can produce an undesirable ‘flattening of the curve’
that is potentially unrecoverable’’ (Levine and Rathmell,
2020). The in-person connections and networking opportu-
nities that so often define academic conferences have gone
by the wayside, with virtual events taking their place in the
COVID era. Whether people prefer to consume data and sci-
ence from their living room or backyard is not as crucial a
question as what the long-term losses to the scientific com-
munity might be from not interacting, congregating around
posters, riffing on pathways, and forging new collaborations.
Although many of the virtual events have been highly effective
and seamless in delivering material, whether the same enthu-
siasm and facilitation of future collaborations are born from
virtual events is not immediately clear. We must be intentionalabout creating opportunities to interact spontaneously with
one another, especially meeting new people. A useful exercise
might be to compare the number of multi-institutional grant
applications and publications over the next 1 to 2 years with
years past, and to delineate how many of them are new col-
laborations or include and feature an early-career investigator.
Within CCC19, we are intentional about putting early-career
investigators and members from underrepresented minority
groups out front and featured on prominent publications. It
is critical that everyone in the scientific research community
recognize that, while the COVID era is difficult for us all, the
effects are not shared equally. Now is the time to lift one
another up.
And finally, it is worth highlighting that efforts to prevent and
treat other non-communicable diseases (NCDs), including can-
cer, have been upended by the COVID-19 pandemic. Pre-
COVID, the World Health Organization prioritized focus and re-
sources on reducing NCDmortality by strengthening health sys-
tems delivering NCD services. In a rapid assessment survey of
service delivery for NCDs during theCOVID-19 pandemic among
163ministries, 122 countries reported that NCD services are dis-
rupted; thus, now is the time for all countries to strive to build
back better systems for the treatment of all patients with
NCDs, including cancer (WHO, 2020).
CONCLUSIONS
The COVID-19 pandemic has resulted in formidable challenges
to patients with cancer as well as clinicians and researchers.
As the pandemic rages on across the world, it will be of para-
mount importance to further study the interactions of cancer
and COVID-19 in order to better tailor the management of pa-
tients with cancer and minimize disruption to cancer care. The
biological mechanisms that underlie the poor outcomes of pa-
tients with cancer remain poorly understood and require further
research to help target therapeutic interventions in patients with
cancer who develop COVID-19. Further research is also needed
to determine whether the biological insights derived from the
cancer research community can be translated into clinically
effective treatments for all patients with COVID-19. Finally,
most of the clinical data in this review originate from high-
resource countries, reflecting the published literature, but more
work is needed to guide the care of patients with cancer during
the pandemic in low-resource settings.
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don, M.S. (2018). Cytokine release syndrome. J. Immunother. Cancer.
https://doi.org/10.1186/s40425-018-0343-9.
Siegel, R.L., Miller, K.D., and Jemal, A. (2020). Cancer statistics, 2020. CA.
Cancer J. Clin. 70, 7–30.
Singer, D.S. (2020). NCI’s work to advance cancer research while responding
to the COVID-19 pandemic. Cancer Cell 37, 746–748.
Smith, J.C., Sausville, E.L., Girish, V., Yuan, M., Lou, Vasudevan, A., John,
K.M., and Sheltzer, J.M. (2020a). Cigarette smoke exposure and inflammatory
signaling increase the expression of the SARS-CoV-2 receptor ACE2 in the
respiratory tract. Dev. Cell 53, 514–529.e3.
Smith,W.R., Atala, A.J., Terlecki, R.P., Kelly, E.E., andMatthews, C.A. (2020b).
Implementation guide for rapid integration of an outpatient telemedicine pro-
gram during the COVID-19 pandemic. J. Am. Coll. Surg. https://doi.org/10.
1016/j.jamcollsurg.2020.04.030.
Somers, E.C., Eschenauer, G.A., Troost, J.P., Golob, J.L., Gandhi, T.N., Wang,
L., Zhou, N., Petty, L.A., Baang, J.H., Dillman, N.O., et al. (2020). Tocilizumab
for treatment of mechanically ventilated patients with COVID-19. Clin. Infect.
Dis. https://doi.org/10.1093/cid/ciaa954.
Stopsack, K.H., Mucci, L.A., Antonarakis, E.S., Nelson, P.S., and Kantoff, P.W.
(2020). TMPRSS2 and COVID-19: serendipity or opportunity for intervention?
Cancer Discov. 10, 779–782.
Sud, A., Jones, M.E., Broggio, J., Loveday, C., Torr, B., Garrett, A., Nicol, D.L.,
Jhanji, S., Boyce, S.A., Gronthoud, F., et al. (2020). Collateral damage: the
impact on outcomes from cancer surgery of the COVID-19 pandemic. Ann.
Oncol. https://doi.org/10.1016/j.annonc.2020.05.009.
Swann, J.B., and Smyth, M.J. (2007). Immune surveillance of tumors. J. Clin.
Invest. https://doi.org/10.1172/JCI31405.
Tang, Y.W., Schmitz, J.E., Persing, D.H., and Stratton, C.W. (2020). Laboratory
diagnosis of COVID-19: current issues and challenges. J. Clin. Microbiol.
https://doi.org/10.1128/JCM.00512-20.Cancer Cell 38, November 9, 2020 645
ll
ReviewTeachey, D.T., Rheingold, S.R., Maude, S.L., Zugmaier, G., Barrett, D.M., Seif,
A.E., Nichols, K.E., Suppa, E.K., Kalos, M., Berg, R.A., et al. (2013). Cytokine
release syndrome after blinatumomab treatment related to abnormal macro-
phage activation and ameliorated with cytokine-directed therapy. Blood 121,
5154–5157.
The Lancet Gastroenterology & Hepatology (2020). Resuming bowel cancer
screening post-COVID-19. Lancet Gastroenterol. Hepatol. https://doi.org/10.
1016/S2468-1253(20)30200-4.
Tian, J., Yuan, X., Xiao, J., Zhong, Q., Yang, C., Liu, B., Cai, Y., Lu, Z., Wang, J.,
Wang, Y., et al. (2020). Clinical characteristics and risk factors associated with
COVID-19 disease severity in patients with cancer in Wuhan, China: a multi-
centre, retrospective, cohort study. Lancet Oncol. 21, 893–903.
Tolaney, S.M., Lydon, C.A., Li, T., Dai, J., Standring, A., Legor, K.A., Capa-
rrotta, C.M., Schenker, M.P., Glazer, D.I., Tayob, N., et al. (2020). The impact
of COVID-19 on clinical trial execution at the dana-farber cancer Institute.
J. Natl. Cancer Inst. https://doi.org/10.1093/jnci/djaa144.
Tuckson, R.V., Edmunds, M., and Hodgkins, M.L. (2017). Telehealth. N. Engl.
J. Med. 377, 1585–1592.
Unger, J.M., Blanke, C.D., LeBlanc, M., and Hershman, D.L. (2020). Associa-
tion of the coronavirus disease 2019 (COVID-19) outbreak with enrollment in
cancer clinical trials. JAMA Netw. Open 3, e2010651.
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